Cwm LLC Sells 12,808 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Cwm LLC trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 3.5% in the first quarter, according to its most recent filing with the SEC. The fund owned 351,677 shares of the biopharmaceutical company's stock after selling 12,808 shares during the period. Cwm LLC's holdings in Gilead Sciences were worth $39,405,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the company. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Gilead Sciences in the 1st quarter valued at about $25,000. Goodman Advisory Group LLC acquired a new stake in shares of Gilead Sciences in the 1st quarter valued at about $29,000. Annis Gardner Whiting Capital Advisors LLC grew its stake in shares of Gilead Sciences by 158.8% in the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock valued at $33,000 after buying an additional 216 shares during the period. Core Alternative Capital grew its stake in shares of Gilead Sciences by 370.8% in the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock valued at $34,000 after buying an additional 241 shares during the period. Finally, Lee Danner & Bass Inc. acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at about $41,000. 83.67% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

GILD has been the topic of several recent research reports. Oppenheimer dropped their price target on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. Cantor Fitzgerald initiated coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price target on the stock. Morgan Stanley raised their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research report on Friday, April 25th. Needham & Company LLC reaffirmed a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. Finally, JPMorgan Chase & Co. raised their price target on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research report on Thursday, March 27th. Nine analysts have rated the stock with a hold rating, fourteen have given a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, Gilead Sciences presently has an average rating of "Moderate Buy" and a consensus target price of $111.38.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $109.64 on Friday. Gilead Sciences, Inc. has a 1 year low of $70.21 and a 1 year high of $119.96. The stock has a market capitalization of $136.38 billion, a P/E ratio of 23.08, a P/E/G ratio of 0.71 and a beta of 0.29. The company's 50-day moving average is $107.74 and its 200 day moving average is $104.68. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.37 and a quick ratio of 1.23.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The company had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. During the same period in the prior year, the firm earned ($1.32) earnings per share. Gilead Sciences's revenue was down .3% on a year-over-year basis. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 27th. Shareholders of record on Friday, June 13th were issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.88%. The ex-dividend date of this dividend was Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is presently 66.53%.

Insiders Place Their Bets

In other Gilead Sciences news, CEO Daniel Patrick O'day sold 10,000 shares of the company's stock in a transaction dated Monday, June 30th. The shares were sold at an average price of $110.45, for a total value of $1,104,500.00. Following the sale, the chief executive officer owned 615,725 shares in the company, valued at approximately $68,006,826.25. This represents a 1.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Johanna Mercier sold 3,000 shares of the company's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $110.17, for a total transaction of $330,510.00. Following the completion of the sale, the insider owned 120,168 shares in the company, valued at approximately $13,238,908.56. This trade represents a 2.44% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 58,500 shares of company stock worth $6,340,745. 0.27% of the stock is currently owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.